Skip to Content

Align Technology Inc

ALGN: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$553.00MpddnnXyxkpqnfc

Align Faces Potential Headwinds if Higher Inflation Takes Bite Out of Consumer Spending

Business Strategy and Outlook

In the nearly 25 years since Align was granted U.S. Food and Drug Administration approval for its clear dental aligners, the Invisalign brand has become synonymous with effective and discreet orthodontic treatment. The serviced addressable market comprises 15 million new orthodontic case starts each year, three fourths of which represent the teen market and the remainder adults. We estimate that Invisalign has achieved low-teens market penetration, largely due to its success at appealing to the adult market. Through two decades of research and development and an unrivaled database from nearly 10 million treated patients, Invisalign is at the forefront of technological innovation in orthodontics, and the company estimates that the system can treat over 90% of malocclusion cases (misaligned teeth).

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of ALGN so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center